Clayton A. Smith - Concepedia

Author

Clayton A. Smith

Also Known As

C A Smith, C Smith, C. A. Smith, C. Smith, C.A. Smith, CLAY SMITH, CLAYTON A. SMITH, Caroline F. Smith, Clay Smith, Clayton A Smith

267

Publications

9.7K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Denver BC Cancer Agency University of British Columbia University of Colorado Anschutz Medical Campus Vancouver General Hospital

About

Clayton A. Smith is an author at University of Colorado Denver specializing in medicine, cell biology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	42	5.5K
2	Health Sciences	12	12	1.9K
3	Biochemistry	2	2	620
4	Natural Sciences	1	1	38
5	Biomolecular Engineering	1	1	38

Clayton A. Smith

Publications

9.1K

Citations

H-Index

Page 1

	Year	Citations
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia Daniel A. Pollyea, Brett M. Stevens, Courtney L. Jones, Nature Medicine Hematological MalignancyMedicineAcute Myeloid LeukemiaStem CellsPharmacology	2018	768
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells Courtney L. Jones, Brett M. Stevens, Angelo D’Alessandro, Cancer Cell Hematological MalignancyBiochemistryMedicineMixed-phenotype Acute LeukemiaPharmacology	2018	539
Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity Robert W. Storms, Aliana P. Trujillo, James B. Springer, Proceedings of the National Academy of Sciences	1999	534
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia Shanshan Pei, Daniel A. Pollyea, Annika Gustafson, Cancer Discovery Mixed-phenotype Acute LeukemiaImmunologyPharmacotherapyImmunotherapyDrug Resistance	2020	518
MIFlowCyt: The minimum information about a flow cytometry experiment Jamie A. Lee, Josef Špidlen, Keith Boyce, Cytometry Part A	2008	494
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial Paul G. Richardson, Albert Oriol, Meral Beksaç, The Lancet Oncology Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapy	2019	375
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies Xiaoyan Jiang, Yun Zhao, Clayton A. Smith, Leukemia Hematological MalignancyBcr-abl Targeted TherapiesMedicineMixed-phenotype Acute LeukemiaMalignant Blood Disorder	2007	357
Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential David G. Kent, Michael R. Copley, Claudia Benz, Blood	2009	335
AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells Shanshan Pei, Mohammad Minhajuddin, Biniam Adane, Cell stem cell Cell AutophagyMitophagyDevelopmental BiologyCell RegulationMedicine	2018	295
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells Brett M. Stevens, Courtney L. Jones, Daniel A. Pollyea, Nature Cancer Hematological MalignancyMixed-phenotype Acute LeukemiaHematologyImmunologyMetabolism Underlies	2020	282

Page 1